Kura Oncology, Inc. — Form 10-Q Summary
Business context and reporting period
Kura Oncology is a clinical-stage biopharmaceutical company developing targeted small-molecule therapeutics for genetically defined solid tumors and blood cancers. The filing covers the quarter and six months ended June 30, 2015, and was filed August 14, 2015. The company completed a reverse merger with public shell company Zeta Acquisition Corp. III on March 6, 2015. Prior Kura was incorporated in August 2014, so no comparable 2014 operating results are presented.
Lead programs included tipifarnib for HRAS-mutant solid tumors and peripheral T-cell lymphoma, KO-947 for MAPK-pathway tumors, and earlier-stage menin-MLL compounds for acute leukemias.
Financial condition and results
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 |
|---|---|---|
| Revenue from product sales | None | None |
| Research and development expense | $4.4 million | $8.0 million |
| General and administrative expense | $1.5 million | $2.6 million |
| Total operating expenses | $5.9 million | $10.6 million |
| Net loss | $5.6 million | $10.1 million |
| Net loss per share | $0.54 | $1.47 |
| Comprehensive loss | $5.6 million | $10.1 million |
| Net cash used in operating activities | Not provided | $7.9 million |
- Cash and cash equivalents were $19.8 million at June 30, 2015, compared with $1.1 million at December 31, 2014.
- Short-term investments were $26.1 million, producing cash, cash equivalents and short-term investments of approximately $45.9 million.
- Total assets were $47.5 million and stockholders’ equity was $43.3 million at June 30, 2015, compared with a $3.4 million stockholders’ deficit at year-end 2014.
- Operating cash use was $7.9 million; investing cash use was $26.3 million, primarily for marketable securities; financing cash provided $52.8 million.
- Financing cash flows included $47.8 million of net common-stock proceeds and $5.0 million from convertible notes. Several earlier convertible notes and accrued interest converted into common stock in connection with the March financing.
- The filing does not report an operating margin because the company had no product revenue. Net loss as a percentage of operating expenses was approximately 94% for the six-month period.
- There was no material bank debt reported at June 30, 2015; the balance sheet showed no convertible notes payable, although the filing describes 2015 note financing and conversions.
Material changes versus the prior comparable period
- No meaningful year-over-year comparison is available because Prior Kura had no operations before August 2014.
- Compared with December 31, 2014, liquidity increased substantially following the March 2015 private placement and related financing transactions.
- The March reverse merger converted the former public shell into the operating Kura Oncology entity. Approximately 14.5 million common shares were issued in the merger, and 5.0 million former Zeta shares were redeemed.
- Research and development spending reflected increased clinical development of tipifarnib, including a Phase 2 trial in HRAS-mutant solid tumors initiated in May 2015, and continued work on KO-947 and other programs.
- Short-term investments increased from zero at year-end to $26.1 million, while accounts payable and accrued expenses increased to $3.6 million, including related-party amounts.
Guidance, outlook, risks and unusual items
- Management expects substantial and increasing operating losses for at least the next several years and expects research and development expenses to rise during the remainder of 2015.
- Management believed existing cash resources would fund requirements for the next twelve months from June 30, 2015, but stated that significant additional financing will be required thereafter. No committed external funding source existed.
- Future funding may come from equity or debt offerings, collaborations, strategic partnerships or licensing arrangements. Additional financing could dilute stockholders, impose restrictive covenants or require relinquishment of valuable rights.
- Key development risks include clinical-trial failure or delay, difficulty enrolling patients with specific genetic alterations, regulatory non-approval, adverse safety findings, companion-diagnostic requirements, reliance on third-party manufacturers and CROs, and limited intellectual-property protection.
- Tipifarnib’s composition-of-matter patents were expected to expire in 2016 in the United States and Europe, increasing reliance on method-of-use patents and regulatory exclusivity.
- License agreements provide for potential development, regulatory and sales milestones totaling up to $81.7 million, plus tiered royalties on net product sales. No milestones had been achieved as of June 30, 2015.
- A $500,000 non-cash license-related research and development expense was recognized during the six months, and the fair value of a UCSF-related derivative liability increased by $307,000.
- Related-party activity included $600,000 of management fee income from Araxes for the six months and research, facility and financing transactions with affiliates.
- In August 2015, the company entered into a 60-month Cambridge facility lease with total base rent of approximately $1.3 million, excluding operating expenses, taxes, insurance and utilities.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective.
Most important facts for investors to verify
- Verify the expected cash runway and timing, amount and terms of future capital raises.
- Confirm the status, classification and conversion terms of the $5.0 million 2015 convertible-note financing, given that no convertible notes payable were shown on the June 30 balance sheet.
- Track Phase 2 enrollment, efficacy and safety results for tipifarnib, particularly in HRAS-mutant tumors and peripheral T-cell lymphoma.
- Assess the remaining patent life, method-of-use protection and regulatory exclusivity available for tipifarnib.
- Review related-party management, research, facility and financing arrangements, including their termination and renewal provisions.
- Evaluate potential dilution from outstanding restricted shares, stock options, future equity financing and registered resale shares.
- Monitor milestone obligations, royalty terms and termination provisions under the company’s license agreements.